MIT Discovery Shows Cells Use Polyamines to Buffer Toxic Iron, Opening New Cancer and Parkinson's Paths

A team at MIT and the Whitehead Institute for Biomedical Research published findings in the journal Cell on August 14 showing that cells use small molecules called polyamines to safely store iron in a non-reactive state. The discovery, led by associate professor Ankur Jain, assistant professor Whitney Henry, and PhD student Pushkal Sharma, solves a decades-old mystery about why cells maintain extraordinarily high levels of polyamines and uncovers a previously unknown defense mechanism against toxic iron overload. The work has implications for both cancer treatment and neurodegenerative disease.

How the Discovery Was Made

The researchers found that when cells have reduced levels of polyamines, a protein called GPX4 becomes essential for survival. GPX4 prevents harmful chemical reactions that damage fatty molecules in cell membranes. Cells with lower polyamine levels also had higher amounts of another protein that acts as an iron sponge, keeping the metal in a mineralized form. To test whether polyamines were directly storing iron, the team developed a new fluorescent sensor that causes living cells to glow based on the amount of chemically reactive iron they contain. By combining this iron sensor with a previously developed polyamine sensor, the researchers observed a striking inverse relationship: as polyamine levels dropped, chemically reactive iron increased.

Cancer Implications

Cancer cells often rely on high polyamine levels to support rapid growth and division, and drugs designed to lower polyamine levels to stop cell division have had limited success. The MIT team's findings suggest that combining polyamine-lowering drugs with GPX4-blocking drugs could be more effective at killing cancer cells than targeting either pathway alone. "When polyamine levels fall, cells rely on GPX4 to protect themselves from iron toxicity," Sharma said. "This could mean that combining drugs that lower polyamine levels with those that block GPX4 might be more effective for killing cancer cells than targeting either pathway alone."

Parkinson's Connection

The discovery may also help explain long-standing observations in early-onset Parkinson's disease. Mutations in genes that help move polyamines around cells are linked to a rare form of early-onset Parkinson's, and scientists have long observed unusually high levels of iron in the brains of Parkinson's patients. While it remains unclear whether excess iron directly contributes to neuron death in Parkinson's, the discovery that polyamines help buffer reactive iron inside cells offers a possible mechanistic link and opens new research directions. Beyond cancer and neurodegeneration, the team expects the fluorescent iron sensor to power new discoveries in aging, metabolism, and basic cell biology.

What to Watch Through Year-End

Three checkpoints follow. Preclinical work on polyamine-plus-GPX4 combination cancer strategies, which the MIT team plans to begin in collaboration with the Koch Institute, will be the first step toward translating the discovery into clinical candidates. Independent replication of the polyamine-iron buffering mechanism, expected from European and Japanese labs working on iron metabolism, will confirm whether the effect holds across cell types and organisms. And follow-on studies on the polyamine-transport genes linked to early-onset Parkinson's, which several research consortia are now pursuing, will determine whether iron chelation or polyamine-supplementation strategies can modify disease progression.